ArticleTurkish journal of physical medicine and rehabilitation2025
Clinical effects of TECAR therapy in the conservative management of Stage 2 lipedema in females: A randomized controlled trial.
Article in Turkish journal of physical medicine and rehabilitation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Non-Invasive Radiofrequency Therapy for Musculoskeletal, Neurological, and Vascular Conditions of the Lower Limb: A Systematic Review and Meta-Analysis.Journal of clinical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: This study aimed to evaluate the clinical efficacy of transfer energy capacitive and resistive (TECAR) therapy in females with Stage 2 lipedema, focusing on limb circumference, pain, functional status, and quality of life. Patients and methods: A prospective, randomized controlled trial was conducted with 30 female patients diagnosed with Stage 2 lipedema between September 2024 and May 2025. Participants were randomized to a TECAR group (n=15; mean age: 52.7±13.1 years; range 39 to 66 years) or a control group (n=15; mean age: 45.9±12.9 years; range, 37 to 59 years). Both groups received compression garments and a structured exercise program. The TECAR group additionally underwent six TECAR sessions over three weeks. Outcomes included lower limb circumference, Visual Analog Scale for pain, Lower Extremity Functional Scale, and Lymphedema Quality of Life Questionnaire-Leg, assessed at baseline and at one and three months after treatment. Results: The groups were comparable at baseline for age (p=0.163) and body mass index (31.85±4.08 kg/m Conclusion: As an adjunct to standard care, TECAR therapy appears to reduce pain and limb volume and enhance overall quality of life in Stage 2 lipedema. Further long-term studies are needed to confirm these findings.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.